Jivan Biologics, a 5-year-old array company based in Berkeley, Calif., threw its hat in the emerging splice-variant array market last week by simultaneously launching 14 separate arrays — 10 of which are for individual gene families — all for use on the Agilent platform.

The only hitch is that Jivan does not have the right to resell Agilent chips, according to a person familiar with the business. This person asked to remain anonymous because of their high-level position at a competing company.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.